近年來，Acinetobacter species所造成成人腦膜炎案例有增加的趨勢，其多抗藥性菌株易使抗生素在使用中很快產生新的抗藥性，影響臨床療效果甚鉅。本研究針對一些從本院成年人腦膜炎病患的腦脊髓液所分離出來的Acinetobater species，測定其對多種臨床常用抗生素的MIC值，這些藥物具備通過血腦障壁blood- brain barrier（BBB）高濃度特性，因此用來治療腦膜炎已有多年。包括imipenem、meropenem、ceftazidime、ceftriaxone、cefepime、aztreonam、ciprofloxacin與sulbactam/ampicillin等。研究結果meropenem的MIC90%為4 μg/mL，ceftazidime的MIC90%為128 μg/mL，由此體外試驗結果可發現治療此類感染疾病使用經驗療法的藥物以carbapenem類藥物是較好選擇，而第三代cephalosporin類藥物如ceftazidime、ceftriaxone則是較不適合之用藥。
 

Acinetobacter spp. isolated from cerebral spinal fluid (CSF) of adult patients with meningitis developed resistance rapidly. This study was to examine the antibiotic minimal inhibitory concentration (MIC) of the Acinetobacter spp. isolated from CSF of adult patients with meningitis. Commoly used antibiotics included in the study had high CSF concentrations and were used for many years, which include ceftazidime, ceftriaxone, cefepime, imipenem, meropenem, aztreonam, ciprofloxacin and subactam/ampicillin. MIC90% was 2 μg/mL for imipenem, 4 μg/mL for meropenem, and 128 μg/mL for ceftazidime. Due to high frequency of drug resistance in such infection, initially empirical therapy with carbapenems is better than that with ceftazidime.